Lihua Elizabeth Budde MD PhD

Hematologic Oncology

Associate Professor, Dept. Of Hematology & HCT, City of Hope

Dept of Heme and HCT1500 East Duarte RoadDuarte, CA 91010
Phone+1 626-256-4673
Fax+1 626-389-3058

Dr. Budde is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Budde's full profile Already have an account?

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 2006 - 2009
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2003 - 2006
Duke UniversityPh.D., 1995 - 2001
Tongji Medical UniversityClass of 1995

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2012 - 2028
WA State Medical License 2006 - 2013

Awards, Honors, & Recognition

Clinical investigator Damon runyon cancer research foundation
CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2016-2017
CMS Meaningful Use Stage 1 Certification Sunrise Acute Care, Allscripts, 2016-2017

Clinical Trials

Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
COMPLETED
PHASE1, PHASE2
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
TERMINATED
PHASE2
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Start of enrollment: 2015 Dec 15
ACTIVE_NOT_RECRUITING
PHASE1

Publications & Presentations

PubMed

1 citations
CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission.
Ibrahim Aldoss, Lior Goldberg, Jianying Zhang, Andrew Artz, Mary C Clark
Blood Advances. 2026-09-08
BAFF-R CAR T-cell therapy for relapsed or refractory B-cell lymphomas.
Lihua E Budde, Marissa M Del Real, Joo Y Song, Lu Chen, Larry W Kwak
Lancet. 2026-09-05
1 citations
A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Rel...
Julio C Chavez, Mariana Bastos-Oreiro, Catherine Diefenbach, Izidore S Lossos, Nirav Shah
American Journal of Hematology. 2026-09-01

Abstracts/Posters

Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy
Lihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in...
Lihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in C...
Lihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

City of Hope Clinical and Laboratory Investigators Present New Research at the 60December 4th, 2018
Rituximab Key to Survival After Transplant for Mantle Cell LymphomaNovember 16th, 2017
$Mosunetuzumab plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed or Refractory Aggressive Large B Cell Lymphoma$
Mosunetuzumab plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed or Refractory Aggressive Large B Cell LymphomaDecember 23rd, 2023